Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect our current expectations as to future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. These statements include, but are not limited to, statements under the heading, "Fiscal 2025 Outlook," "Modeling Assumptions," and those related to our expectation ...

Financial Performance & Growth - Q2 2025 revenue reached $725 million, a 3% increase compared to Q2 2024[5] - Adjusted EBITDA for Q2 2025 was $184 million, up 13% from Q2 2024[5] - Adjusted EPS for Q2 2025 increased by 56% to $025, compared to $016 in Q2 2024[5] - The company is increasing its 2025 adjusted EBITDA guidance range to $665 million - $685 million[5] - Net revenues are projected to be between $30 billion and $31 billion in 2025, representing a 7% to 11% increase[11] Segment Performance - Specialty segment revenue increased by 13% in the first half of 2025[5] - Affordable Medicines segment revenue increased by 4% in the first half of 2025[5] - AvKARE segment revenue increased by 1% in the first half of 2025[5] - AvKARE revenue reached $663 million in 2024, with a 23% compound annual growth rate (CAGR) from 2020 to 2024, and is projected to exceed $900 million by 2027[24] Product & Pipeline Development - CREXONT is on track to achieve peak U S sales of $300 million to $500 million[39] - The company expects to file a Biologics License Application (BLA) for an omalizumab biosimilar (bXOLAIR) in Q4[5] - The company launched 15 new products in the Affordable Medicines portfolio year-to-date[5]

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2024 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; our future results of operations and financial posi ...

Financial Performance - Consolidated revenue increased by 70% to $403 million[13] - Adjusted EBITDA rose by 77% to $129 million[13] - AFFO increased significantly by 759% to $28 million[13] - America segment revenue increased by 44% to $303 million[14] - Airports segment revenue increased significantly by 156% to $100 million[17] Segment Highlights - America's digital revenue grew by 111% to $114 million[16] - Airports' digital revenue increased by 315% to $64 million[19] - Site lease expense for America increased by 111% to $94 million[16] - Site lease expense for Airports increased by 134% to $60 million[19] Capital Structure - Debt decreased by $226 million, reaching $5067 billion[24]

Q2 2025 EARNINGS | August 5, 2025 DISCLAIMER Certain statements in this presentation may constitute "forward-looking" statements and information within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events, including, without limitation, statements regarding future financial or operating performa ...

Financial Performance - Second quarter revenue reached $19993 thousand, a 75% increase year-over-year compared to $11430 thousand in the second quarter of 2024[12] - The company's GAAP gross margin was -196% in the second quarter of 2025, compared to -205% in the second quarter of 2024[12] - Non-GAAP gross margin was -174% in the second quarter of 2025, compared to -168% in the second quarter of 2024[12] - GAAP net loss was $15430 thousand in the second quarter of 2025, compared to $12241 thousand in the second quarter of 2024[12] - Non-GAAP net loss was $11213 thousand in the second quarter of 2025, compared to $10730 thousand in the second quarter of 2024[12] Outlook for Third Quarter 2025 - The company expects revenue to be between $18 million and $24 million[13] - Non-GAAP gross profit is projected to be between -$24 million and -$06 million[13] - Non-GAAP gross margin is expected to range from -134% to 25%[13] - Adjusted EBITDA is forecasted to be between -$108 million and -$68 million[13]

Second Quarter 2025 Financial Results Conference Call Presentation August 5, 2025 Together, Building the Future Safe Harbor Statement 3 Key Priorities This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions with respect to the future and Uniti management's current expectations, involve certain risks and uncertainties, and are not guarantees. These forward-looking statements include, ...

Piloted Wingborne Flights Vertical Aerospace H1 2025 Earnings Call ©VerticalAerospaceGroup Ltd 2025. All rights reserved. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securitie ...

Financial Performance - Revenue was $1.6 billion, down 1% ex-FX, consistent with the phasing of the Loss of Exclusivity (LOE) of Atozet[12] - Adjusted EBITDA was $522 million, representing a 32.7% Adjusted EBITDA margin[12] - The company raised full-year 2025 revenue guidance by $100 million at the midpoint, while the Adjusted EBITDA range was affirmed[12] - The company repaid $345 million of long-term debt and is on track to achieve net leverage below 40x by year-end[12] - Adjusted Gross Margin was 617% for both Q2 2025 and YTD 2025, compared to 620% for Q2 2024 and YTD 2024[30] Segment Performance - Women's Health revenue increased by 3% to $462 million in Q2 2025, and 6% YTD to $925 million[14] - Biosimilars revenue increased by 5% to $173 million in Q2 2025, but decreased 6% YTD to $314 million[18] - Established Brands revenue decreased by 3% to $936 million in Q2 2025, and 7% YTD to $1822 billion[23] Product Performance - Nexplanon revenue decreased 1% to $240 million in Q2 2025, but increased 6% YTD to $488 million[14] - Follistim AQ revenue increased 18% to $74 million in Q2 2025, and 31% YTD to $142 million[14] - Hadlima revenue increased 78% to $50 million in Q2 2025, and 66% YTD to $96 million[18]

Financial Performance - Q2 2025 revenue reached a record of $163 million, driven by a 26% year-over-year increase in Marketplace revenue[16] - Gross profit for Q2 2025 was a record $65.2 million, a 23% year-over-year increase, fueled by a 34% year-over-year growth in Marketplace gross profit[16] - The Marketplace gross margin for Q2 2025 was 35.4%, a 190 basis point increase year-over-year, attributed to AI pricing and selection[16] - Adjusted EBITDA for Q2 2025 was $3.9 million, an increase of $6.6 million year-over-year[14, 16] - FY24 Total Revenue was $546 million, a 18% year-over-year increase[27] Growth Initiatives - Active Buyers increased by 22% year-over-year in Q2 2025, driven by increased enterprise penetration and Teamspace adoption[15, 17] - Active Suppliers increased by 28% year-over-year in 2024[15, 17] - International revenue grew by 31% year-over-year, representing 18% of Marketplace revenue in Q2[18, 37] Future Outlook - The company is targeting 20% incremental Adjusted EBITDA margins as it scales to $1 billion[19] - For Q3 2025, the company expects revenue of $167-169 million, representing 18-19% growth year-over-year[70] - For FY 2025, the company expects total revenue growth of at least 20%[70]